Parenteral viral hepatitis prevention program 2019-2022 (National program)

Parenteral viral hepatitis prevention program 2019-2022 (National program)

Virus targets
Hepatitis B
Hepatitis C
Type
Testing and treatment implementation
Setting
National
Other targets
HIV
Phase
Active
Health outcomes
Mortality
WHO region
European Region
Country
Armenia
Key interventions
Blood safety
Community mobilization
Hepatitis B Vaccination
Injection safety and infection control
Persons who inject drugs: HCV cure as prevention
Persons who inject drugs: Medication assisted therapy
Persons who inject drugs: Syringe service program(s)
Prevention mother-child transmission
Strategic data analysis
Testing and diagnosis
Treatment (direct or referral)
Target population
Adolescents (10 - 19 years of age)
Adults
All ages
Birth cohorts of adults
Children (> one year < 10 years of age)
Household contact(s)
Infants (less than one year of age)
Newborn (born in last 30 days)
Occupations with possible exposure
Persons who inject drugs
Pregnant women
Sexual contact(s)
Performance target
Blood safety
Care cascade: Evidence of current infection
Care cascade: HBV diagnosis
Care cascade: HBV testing
Care cascade: HCV diagnosis
Care cascade: HCV testing
Care cascade: HCV treatment
Harm reduction (access to safe injection equipment for persons who inject drugs)
HBV prevention of mother to child transmission
Hepatitis B vaccination coverage
Injection safety
If you would like to have a program page for your program, please create an account and submit program information here

Performance target additional info

Decrease mortality by 34%, decrease morbidity by 10%, provide treatment among 75% diagnosed people

Last updated